Cerebrospinal fluid β-amyloid 1-42 correlates with rate of progression in Alzheimer's disease (Q50763390)

18 March 2018

title

Cerebrospinal fluid β-amyloid 1-42 correlates with rate of progression in Alzheimer's disease (English)

1 reference

18 March 2018

0 references

George S Vlachos

1 reference

18 March 2018

George P Paraskevas

series ordinal

1 reference

18 March 2018

Dimitris Naoumis

series ordinal

1 reference

18 March 2018

Elizabeth Kapaki

series ordinal

1 reference

18 March 2018

publication date

30 March 2012

1 reference

18 March 2018

Journal of Neural Transmission

published in

1 reference

18 March 2018

volume

119

1 reference

18 March 2018

issue

1 reference

18 March 2018

page(s)

799-804

1 reference

18 March 2018

Frontotemporal lobar degeneration: recent progress in antemortem diagnosis

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Cognitive deterioration in Alzheimer's disease: is the early course predictive of the later stages?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Global prevalence of dementia: a Delphi consensus study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Aggressive course of disease in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Correlation between Cognitive Impairment and CSF Biomarkers in Amnesic MCI, non-Amnesic MCI, and Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Biological markers of amyloid beta-related mechanisms in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

CSF tau protein and beta-amyloid (1-42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

CSF biomarkers predict rate of cognitive decline in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Comparing predictors of conversion and decline in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

CSF biomarkers: pinpointing Alzheimer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

The diagnostic value of cerebrospinal fluid tau protein in dementing and nondementing neuropsychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

CSF biomarker profile and diagnostic value in vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

The epidemiology of the dementias: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Rapidly progressive Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian imaging, biomarkers and lifestyle (AIBL) study of ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Protein misfolding and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

CSF biomarkers predict a more malignant outcome in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-012-0798-7

Alzheimer's disease a century later.

21 January 2018

1 reference

12 December 2020

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

1 reference

12 December 2020

Predictive factors for rapid loss on the mini-mental state examination in Alzheimer's disease.

1 reference

12 December 2020

Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years

1 reference

12 December 2020

Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis.

1 reference

12 December 2020

Rapid cognitive decline in Alzheimer's disease. Consensus paper.

1 reference

12 December 2020

10.1007/S00702-012-0798-7

Identifiers

DOI

1 reference

18 March 2018

1 reference

18 March 2018